DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for June 9, 2026, at 9:20 AM ET in Miami, with a live webcast and 90-day replay on the company’s investor website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DBVT was down 0.68% while closely related biotech peers also traded lower: CADL -7.3%, OMER -4.35%, ANNX -2.22%, CAPR -4.02%, NGNE -3.6%. Despite this, the momentum scanner did not flag a coordinated sector move, suggesting today’s setup reflects stock-specific dynamics rather than a broad, high-conviction sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | THRIVE trial start | Positive | -2.9% | First participant screened in THRIVE Phase 2 VIASKIN Peanut Patch study. |
| May 13 | General meeting notice | Neutral | +1.2% | Announcement and logistics for June 3, 2026 Combined General Meeting. |
| May 12 | Investor conference | Neutral | -2.0% | CEO fireside chat at H.C. Wainwright BioConnect investor conference. |
| Apr 30 | Q1 2026 earnings | Neutral | -5.4% | Reported Q1 2026 results, cash level and net loss for the quarter. |
| Apr 02 | Share count update | Neutral | -3.3% | Updated total shares and voting rights as of March 31, 2026. |
Recent company updates, including positive clinical and financing milestones, have often been followed by negative or mixed next-day price reactions.
Over the last few months, DBV Technologies has reported several milestones. A key Phase 2 THRIVE study for the VIASKIN Peanut Patch in infants was initiated on Jun 2, 2026, yet the stock fell 2.91% the next day. Participation in investor conferences (May 12, 2026) and the scheduling of the Jun 3, 2026 general meeting drove only modest, mixed moves. Q1 2026 results on Apr 30 showed $229M cash and a $47.6M net loss, followed by a 5.38% decline. Routine voting-rights disclosure on Apr 2 coincided with a 3.32% drop.
Market Pulse Summary
This announcement highlights DBV Technologies’ participation in a major healthcare investor conference, providing additional visibility for its late-stage peanut allergy program. The fireside chat on June 9, 2026 and a 90-day webcast replay offer extended exposure to institutional audiences. Recent history includes Phase 2 THRIVE trial progress and Q1 2026 financials with $229M cash and a $47.6M net loss. Investors may watch for any new clinical, regulatory, or strategic disclosures made during the event.
AI-generated analysis. Not financial advice.
Châtillon, France, June 5, 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL.
A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
